내시경 시장 : 제품 유형, 사용성, 영상 기술, 최종 사용자, 용도별 - 세계 시장 예측(2026-2032년)

The Endoscopy Market is projected to grow by USD 80.39 billion at a CAGR of 7.99% by 2032.

Endoscopy Executive Summary

Endoscopy is a core pillar of modern minimally invasive care, supporting diagnosis, biopsy, screening, surveillance, and therapy across gastroenterology, pulmonology, urology, gynecology, ENT, and surgical specialties. Demand is reinforced by aging populations, higher chronic disease burden, improved cancer screening participation, and the shift from inpatient procedures to ambulatory and outpatient settings.

Verified public health data underscores the need for scalable endoscopy capacity. The International Agency for Research on Cancer reported more than 1.9 million new colorectal cancer cases and more than 900,000 colorectal cancer deaths globally in 2022, while U.S. screening guidance recommends routine colorectal cancer screening for adults ages 45 to 75. These facts position endoscopy as a high-value clinical and economic priority for health systems, payers, and medical technology stakeholders.

Transformative Shifts Reshaping Endoscopy

The endoscopy landscape is shifting from equipment-centric purchasing to value-based, workflow-integrated care delivery. Hospitals and ambulatory surgery centers are prioritizing high-definition visualization, single-use endoscopes in selected procedures, automated reprocessing compliance, ergonomic system design, and connected procedure documentation to reduce infection risk, improve throughput, and standardize quality.

Regulation and reimbursement are also reshaping adoption decisions. The EU Medical Device Regulation has raised clinical evidence and post-market surveillance expectations, while FDA safety communications have kept reprocessing, infection prevention, and device design under close scrutiny. At the same time, outpatient endoscopy, capsule endoscopy, endoscopic ultrasound, advanced therapeutic endoscopy, and image-guided interventions are expanding the role of endoscopy beyond traditional diagnostic workflows.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in endoscopy rather than a standalone feature. AI-assisted computer-aided detection and characterization systems are being applied to colon polyp detection, Barrett's esophagus assessment, bleeding detection, image enhancement, automated reporting, and quality measurement. In 2021, the U.S. FDA authorized the first AI-based device to help clinicians detect potential colorectal lesions during colonoscopy, validating the category's clinical direction.

The impact extends across the care pathway. AI can support higher adenoma detection rates, reduce observer variability, improve documentation completeness, and enable performance benchmarking across endoscopy units. Adoption must be governed by prospective validation, representative datasets, cybersecurity controls, privacy compliance, and clear accountability so that AI augments clinicians without weakening clinical oversight.

Key Regional Insights: Global Endoscopy Demand

Asia-Pacific is a major growth engine for endoscopy, supported by expanding hospital infrastructure, large patient populations, rising cancer screening awareness, and strong technology adoption in Japan, China, South Korea, Australia, and India. The region also faces a rising digestive disease and cancer burden, making endoscopic diagnosis, early detection, and minimally invasive treatment increasingly important for tertiary hospitals and specialty centers. North America remains a mature but innovation-intensive region, with the United States leading in ambulatory endoscopy, AI adoption, advanced therapeutic procedures, and reimbursement-linked quality measurement, while Canada emphasizes standardized access through publicly funded care pathways.

Europe benefits from organized screening programs, established gastroenterology networks, and strong clinical evidence standards, although Medical Device Regulation compliance has increased regulatory complexity and documentation requirements. Latin America is improving access through private hospital investment and public screening initiatives, particularly in Brazil and Mexico, while the Middle East is expanding advanced care capacity through national health transformation programs and specialty hospital development across GCC markets. Africa remains underpenetrated because of workforce, training, equipment, and infrastructure constraints, but long-term demand is supported by urbanization, noncommunicable disease growth, expanding tertiary care investment, and the need for earlier diagnosis of gastrointestinal and respiratory conditions.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining momentum as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand hospital capacity, medical tourism, and universal health coverage priorities, creating greater demand for cost-effective endoscopy systems, accessories, training, and service support. The GCC is investing heavily in specialty care, digital health, and premium hospital infrastructure, creating demand for advanced visualization, endoscopic ultrasound, integrated operating room platforms, infection-control solutions, and clinician upskilling.

The European Union is defined by strong clinical governance, colorectal cancer screening infrastructure, data protection requirements, and stricter Medical Device Regulation evidence obligations. BRICS countries combine large procedural volumes with localization policies, expanding public hospital networks, and price-sensitive procurement, making manufacturing scale, clinical education, and service networks critical. G7 markets lead in innovation, evidence generation, reimbursement frameworks, aging-population care pathways, and AI-enabled workflow adoption, while NATO member markets increasingly emphasize resilient medical supply chains, cybersecurity, interoperability, and procurement reliability across healthcare systems.

Key Country Insights: Priority Endoscopy Markets

The United States leads global endoscopy innovation through high procedure volumes, ambulatory surgery center expansion, advanced reimbursement systems, cancer screening infrastructure, and early AI adoption. Canada emphasizes publicly funded access, quality standardization, and organized screening, while Mexico is expanding private hospital capacity and cross-border medical services. Brazil is Latin America's largest endoscopy opportunity due to population scale, specialist hospital networks, and increasing demand for gastrointestinal diagnosis and minimally invasive procedures.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from screening programs, established endoscopy societies, aging populations, and demand for productivity-enhancing platforms, while Russia presents a more localized procurement and supply-chain environment. China combines large unmet need, domestic manufacturing growth, hospital modernization, and policy support for advanced medical infrastructure; India offers high long-term potential through private healthcare expansion, rising gastrointestinal disease diagnosis, and increasing access to specialty care. Japan and South Korea are leaders in high-definition imaging, early cancer detection, and technologically advanced endoscopy practice, while Australia maintains strong screening infrastructure, quality-led adoption, and well-developed outpatient care pathways.

Actionable Recommendations for Endoscopy Leaders

Industry leaders should align product strategy with clinical outcomes, regulatory evidence, and operational efficiency. Priority actions include investing in AI systems validated through prospective studies, expanding single-use and hybrid endoscope portfolios where infection-control economics are favorable, strengthening reprocessing education, and designing platforms that integrate imaging, reporting, pathology, and electronic health records.

Commercial success will depend on regional execution. Organizations should localize pricing and service models, build training partnerships with clinical societies, support ambulatory endoscopy workflows, and create resilient supply chains for scopes, processors, accessories, consumables, and repair services. Leaders that combine clinical evidence, workflow productivity, cybersecurity readiness, and lifecycle cost transparency will be best positioned for procurement wins.

Research Methodology

This executive summary is built using a structured research methodology that combines secondary research, expert interpretation, and data triangulation. Sources considered include public health agencies, cancer registries, regulatory databases, clinical guidelines, peer-reviewed research, hospital procurement trends, and recognized organizations such as WHO, IARC, CDC, FDA, OECD, Eurostat, and national screening authorities.

The analysis evaluates demand drivers, regulatory shifts, technology adoption, procedure migration, infection-control requirements, regional access patterns, and macroeconomic indicators. Insights are validated by cross-checking multiple credible sources and prioritizing data that is transparent, current, and relevant to endoscopy devices, accessories, software, services, and care delivery models.

Conclusion: Endoscopy Growth Outlook

Endoscopy is entering a new phase defined by minimally invasive intervention, digital visualization, AI-enabled quality improvement, and outpatient care expansion. The sector's fundamentals remain strong because endoscopy directly supports cancer detection, chronic disease management, procedural efficiency, and health system cost containment.

The next competitive cycle will reward organizations that demonstrate clinical value, regulatory readiness, infection-control discipline, and regional adaptability. As hospitals and ambulatory centers modernize their endoscopy suites, suppliers that deliver trusted technology, training, service reliability, and measurable workflow gains will be positioned to support sustainable endoscopy adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopy Market, by Product Type

• 7.1. Endoscope
  • 7.1.1. Flexible Endoscopes
    • 7.1.1.1. Bronchoscopes
    • 7.1.1.2. Colonoscopes
    • 7.1.1.3. Cystoscopes
    • 7.1.1.4. Duodenoscopes
    • 7.1.1.5. Gastroscopes
  • 7.1.2. Rigid Endoscopes
    • 7.1.2.1. Arthroscopes
    • 7.1.2.2. Hysteroscopes
    • 7.1.2.3. Laparoscopes
• 7.2. Visualization & Documentation Equipment
• 7.3. Operative Devices & Accessories

8. Endoscopy Market, by Usability

• 8.1. Disposable
• 8.2. Reusable

9. Endoscopy Market, by Imaging Technology

• 9.1. Fiber Optic Endoscopy
• 9.2. Video Endoscopy

10. Endoscopy Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Hospitals

11. Endoscopy Market, by Application

• 11.1. Gastrointestinal
• 11.2. Gynecological
• 11.3. Respiratory
• 11.4. Urological

12. Endoscopy Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Endoscopy Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Endoscopy Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Ackermann Instrumente GmbH
• 16.2. Ambu A/S
• 16.3. Arthrex, Inc.
• 16.4. Avanos Medical, Inc.
• 16.5. B. Braun Melsungen AG
• 16.6. Boston Scientific Corporation
• 16.7. CapsoVision, Inc.
• 16.8. CONMED Corporation
• 16.9. Cook Medical LLC
• 16.10. EndoMed Systems GmbH
• 16.11. FUJIFILM Holdings Corporation
• 16.12. Hologic, Inc.
• 16.13. Hoya Corporation
• 16.14. Intuitive Surgical, Inc.
• 16.15. Johnson & Johnson
• 16.16. KARL STORZ SE & Co. KG
• 16.17. Medtronic PLC
• 16.18. Mindray Medical International Limited
• 16.19. Olympus Corporation
• 16.20. Pentax Medical Company
• 16.21. Richard Wolf GmbH
• 16.22. Scivita Medical Technology Co., Ltd.
• 16.23. Smith & Nephew plc
• 16.24. STERIS Corporation
• 16.25. Stryker Corporation
• 16.26. Verathon Inc. by Roper Industries, Inc.
• 16.27. Zimmer Biomet Holdings, Inc.
• 16.28. Zsquare Ltd.